ClinicalTrials.gg
RecruitingNCT06096805Updated Jun 7, 2024

Prediction of Placental Fetal Growth Restriction in High Risk Population (PoPFGR)

An observational study in Fetal Growth Retardation, sponsored by Shanghai First Maternity and Infant Hospital. Recruiting at 1 site in China. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2024-06-07.

Sponsored by Shanghai First Maternity and Infant Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

This study intends to prospectively enroll high-risk pregnant women to establish a multicenter cohort. By combining maternal basic characteristics, medical history, early pregnancy ultrasound, and biological markers, we aim to construct a joint predictive model for MVM-FGR.

Read the detailed description

Clinical guidelines do not recommend clinical screening for MVM-FGR in low-risk populations. Predictive models for FGR are often based on preeclampsia prediction models or Down syndrome serum screening models, which have limited utility. This study aims to establish a multi-center prospective cohort of pregnant women at high risk for FGR. We will collect baseline characteristics of pregnant women, ultrasound measurements of fetal growth, structural scans, maternal-fetal Doppler blood flow, as well as maternal serum and plasma in first and mid-trimester. Serum and plasma biomarker testing will be conducted. We will regularly observe fetal growth data, maternal-fetal complications during pregnancy, and collect delivery information, conditions of the newborn and placental pathology results after birth. By integrating maternal medical history, serum and plasma biomarkers, Doppler ultrasound, and other factors, we will establish a combined predictive model for early and mid-term MVM-FGR.

02

Conditions studied

  • Fetal Growth Retardation
03

In context

Fetal Growth Retardation

262 studies on the registry are indexed under Fetal Growth Retardation; 69 are open to participants now.

This study's planned enrollment of 2,000 is above the median of 200 across 145 observational studies indexed under Fetal Growth Retardation.

Browse Fetal Growth Retardation studies →

Lead sponsor

Shanghai First Maternity and Infant Hospital is the lead sponsor of 48 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Sampling method
Probability sample

Study population

First trimester pregnancy women who are at higher risk of fetal growth restriction.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant women with gestational age of \<14 weeks
  • Maternal age between 18 and 45 years old
  • With at least one of FGR high risk factors:

    1. Maternal age >40 years
    2. Nulliparous, Maternal age >38 years
    3. Previous pregnancy with FGR, PE or placental abruption
    4. Maternal medical history of chronic hypertension, diabetes mellitus, chronic nephritis or diseases (such as SLE or APS)
    5. Recurrent spontaneous abortion (RSA) > 3 times with unknown causes
  • Or with at least two of the following FGR high risk factors:

    1. Maternal age 35\~40 years
    2. ≥ 28 kg/m2 or BMI \< 18.5 kg/m2
    3. Conception with assisted reproductive technology
    4. Interval from previous delivery: > 5 years or \< 6 months

Exclusion criteria

Exclusion Criteria:

  • Presence of fetal genetic abnormalities or severe structural abnormalities in prenatal ultrasound or genetic testing.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Present of maternal-vascular-malperfusion (MVM)-FGR

    Development of MVM Fetal growth restriction

    Time frame: during the pregnancy, up to an average gestational age of 40 weeks

Secondary outcomes

  1. Other adverse pregnancy outcome

    including miscarriage, preeclampsia; intrauterine fetal death

    Time frame: pregnancy-born after 28 days

  2. GA at delivery, birth weight, neonatal outcomes.

    GA at delivery, birth weight, neonatal outcomes.

    Time frame: the day at birth

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Dec 2025, 28 months after the start.

Of 72 non-industry observational studies under Fetal Growth Retardation, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 170. This study's planned 28 months is below that.

Counting every sponsor, half of 73 studies reached it within 52 months; a quarter within 24 and three quarters within 170.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2023
First posted
Oct 24, 2023
StartActual
Aug 10, 2023
Primary completionEst.
Dec 30, 2025
CompletionEst.
Dec 30, 2025
Last update
Jun 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06096805
Lead sponsor
Shanghai First Maternity and Infant Hospital
Responsible party
Luming Sun (Professor, Shanghai First Maternity and Infant Hospital) — Principal investigator
First posted
Oct 24, 2023
Start date
Aug 10, 2023
Primary completion
Dec 30, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Jun 7, 2024

Study contacts

Jianping Chen, Master
Contact
urchin_chen@163.com
13916159565 ext. +86
Luming Sun, Docter
principal investigator · Shanghai First Maternity and Infant Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion